首页> 外文期刊>Journal of the Canadian Association of Gastroenterology >A MULTI-CENTRE RANDOMIZED CONTROLLED TRIAL TO COMPARE TWO BOWEL CLEANSING REGIMENS AFTER A COLONOSCOPY WITH INADEQUATE BOWEL PREPARATION
【24h】

A MULTI-CENTRE RANDOMIZED CONTROLLED TRIAL TO COMPARE TWO BOWEL CLEANSING REGIMENS AFTER A COLONOSCOPY WITH INADEQUATE BOWEL PREPARATION

机译:一种多中心随机对照试验,以比较结肠镜检查后的两个肠道清洁方案,肠道准备不足

获取原文
           

摘要

Aims Failed bowel preparation is common during colonoscopy, yet the optimal purgative regimen to use for the next attempt is unknown. The objective of this study was to compare the efficacy, tolerability, and safety of two regimens at supratherapeutic doses for use after failed bowel preparation. Methods A multi-centre phase III endoscopist blinded randomized controlled trial (NCT02976805) was conducted in patients who failed bowel preparation, using the US Multi-Society Task Force (USMSTF) definition of inability to exclude polyps 5 mm in size and requiring a shortened interval to next colonoscopy. Regimen A consisted of 15 mg of bisacodyl and 2 2 L of split dose polyethylene glycol electrolyte solution (PEG) and Regimen B consisted of 15 mg of bisacodyl and 4 2 L of split dose PEG. The primary outcome was adequate bowel preparation, defined as a Boston Bowel Preparation Scale (BBPS) total score ≥ 6 with all segment scores ≥ 2. Secondary outcomes were adequate bowel preparation using the USMSTF definition, median BBPS, adenoma detection (ADR), advanced adenoma detection (aADR), sessile serrated polyp detection (SSPDR), and cecal intubation (CIR). Adverse events were assessed at the time of the colonoscopy and 14 days later. Results Between February 2017 and December 2019, 250 subjects were screened at four academic centres in Canada, of which 195 were randomized: 96 to Regimen A and 99 to Regimen B. The mean (SD) age was 60.6 (11.4) years, 87 (45.1%) were female, and the median (IQR) total BBPS score at previous failed colonoscopy was 3 (1,4). Regimen B was not superior to Regimen A in achieving adequate bowel preparation using the BBPS definition (87.6% vs. 91.1%, p=0.45) or the USMSTF definition (85.4% vs 91.1%, p=0.24), nor was it superior with respect to the median BBPS score (7 vs 7, p=0.50), mean ADR (31.5% vs 37.8%, p=0.37), aADR (11.2% vs 18.9%, p=0.15), SSPDR (5.6% vs 8.9%, p=0.40) or CIR (92.1% vs 96.7%, p=0.19). Regimen A had a higher adherence rate (88.2% vs. 74.7%, p=0.02) and greater willingness to undergo the bowel preparation again (91.2% vs. 66.2%, p0.001). The only serious adverse event occurred in a patient randomized to Regimen B who was admitted to hospital for vomiting after colonoscopy. Conclusions Split dose 4L PEG with 15mg of bisacodyl is highly efficacious, well tolerated, and can be used for patients who previously failed first line bowel preparations. The additional 2L of PEG in Regimen B did not improve bowel preparation and was not as well tolerated. Funding Agencies AMOSO Opportunities Grant, Pharmascence Inc.
机译:目的在结肠镜检查期间,肠道准备失败的肠道制剂是常见的,但是用于下一次尝试的最佳泻药方案是未知的。本研究的目的是比较Supraterapeutic剂量的两种方案的疗效,耐受性和安全性,以便在失败的排便后使用。方法使用美国多社会任务力(USMSTF)无能为力的患者进行肠道准备失败的患者,在失败的患者中进行多中心阶段III内窥镜盲(NCT02976805)的多中心阶段III内窥镜对照试验(NCT02976805)。缩短到下一个结肠镜检查。方案A由15mg BisacodyL和2 2L分裂剂量聚乙二醇电解质溶液(PEG)和方案B组成,由15mg的双乙二酸和4磅分裂剂量PEG组成。主要结果是足够的肠道制剂,定义为波士顿肠道制备量表(Bbps)总分≥6,所有段评分≥2。二次结果使用USMSTF定义,中位数Bbps,腺瘤检测(ADR),先进是足够的肠道准备腺瘤检测(AADR),术锯齿状息肉检测(SSPDR)和CECAL插管(CIR)。在结肠镜检查时评估不良事件,并在14天后评估。结果2017年2月至2019年12月,加拿大四个学术中心筛选了250名科目,其中195年被随机分组​​:96举行举行的举行方案B.平均(SD)年龄为60.6(11.4)年(11.4)岁( 45.1%)是女性,中位数(IQR)在先前发生的结肠镜检查中的BBPS总分为3(1,4)。使用BBPS定义(87.6%与91.1%,p = 0.45)或USMSTF定义(85.4%Vs 91.1%,P = 0.24),方案B不优于方案A不优于实现足够的肠道制剂(85.4%,P = 0.24),也不是优越的尊重中值Bbps评分(7 Vs 7,P = 0.50),平均ADR(31.5%Vs 37.8%,P = 0.37),AADR(11.2%Vs 18.9%,P = 0.15),SSPDR(5.6%VS 8.9% ,p = 0.40)或CIR(92.1%vs 96.7%,p = 0.19)。方案A具有更高的粘附率(88.2%与74.7%,P = 0.02),并且更加愿意再次接受肠道制剂(91.2%vs.66.2%,P <0.001)。患者唯一严重的不良事件发生在随机的患者中,该患者在结肠镜检查后被录取为呕吐。结论分裂剂量4L PEG,15毫克双胞外体具有高度有效,耐受性,可用于先前失败的第一线肠道制剂的患者。额外的2L栓中的PEG在B B中没有改善肠道制剂,并且不太容忍。资助机构Amoso机会Grant,Pharmasssssscence Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号